1. Ludwing J, Viggiano TR, McGill DB, Oh
Bj. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hiterto unnamed disease.
Mayo Clinic Proc. 1980; 55: 434-B.
2. Wanless IR, Lentz JS. Fatty liver
(steatohepatitis) and obesity: an autopsy study with analisys of risk factors. Hepatology
1990; 12:1106-10.
3. Powell EE, Cooksley WG, Hanson R,
Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a
follow-up study of forty two patients for up to 21 years. Hepatology 1990; 11:74-80.
4. Storey E, Anderson GJ, Mack U, Powell
LW, Halliday JW. Desialylated transferrin as a serologycal marker of chronic excessive
alcohol ingestion. Lancet 1987; 1:1292-4.
5. Propst A, Propst T, Judmaier G, Vogel
W. Prognosis in alcoholic nonalcoholic steatohepatitis (letter). Gastroenterology. 1995;
108:1607.
6. NonomuraA, Mizukami Y, Unoura M,
Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in
non-alcoholics; nonalcoholic steatohepatitis and fibrosis. Gastroenterol Jpn.
1992;27-521-8.
7. Lee RG. Non alcoholic steatohepatitis
: a study of 49 patients . Hum Pathol. 1989; 20:594-8.
8. Eriksson S, Eriksson KF, Bondesson L.
Nonalcoholic steatohepatitis in obesity: a reversible condition . Acta Med Scand. 1986;
220:83-8.
9. Baldrige AD, Perez-Atayde AR,
Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a
multicenter retrospective study. J Pediatr. 1995; 127:700-4.
10. Moran JR, Ghishan FK, Halter SA,
Greene HL. Steatohepatitis in obese children: a cause of chronic disfunction. Am J
Gastroenterol. 198378:374-7.
11. Itoh S. Yougel T, Kawagoe K.
Comparison between nonalcoholic steatohepatitis an alcoholic hepatitis. Am J Gastroenterol
1987; 82:650-4.
12. Bacon BR, Farahvash MJ, Janney CG,
Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity.
Gastroenterology. 1994:107:1103-9.
13. Diehl AM, Goodman Z, Ishak KG.
Alcoholike disease in nonalcoholics. A clinical and histologic comparison with
alcohol-induced liver injury. Gastroenterology. 1988; 95:1056-62.
14. Pinto HC, BaptistaA, Camilo ME,
Valente A, Saragoca A, de Moura MC.Nonalcoholic steatohepatitis. Clinicopathological
comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci.
1996;41:172-9.
15. Craig RM, Neumann T, Jeejeebhoy KN,
Yokoo H. Severe hepatocelular reaction resembling alcoholic hepatitis with cirrosis after
massive small bowel resection and prolonged total parenteral nutrition . Gastroenterology.
1980; 79:131-7.
16. Clain DJ, Lefkowicht JH. Fatty liver
disease in morbid obesity. Gastroenterol Clin North Am. 1987; 16:239-52.
17. Schaffner F, Thaler H. Nonalcoholic
fatty liver disease. Prog Liver Dis. 1986; 8:283-98.
18. Nazim M, StampG, Hodgson HJ.
Nonalcoholic steatohepatitis asociated with small intestinal diverticulosis and bacterial
overgrowth. Hepatogastroenterology. 1989; 36:359-51.
19. Hamilton DL, Vest TK, Brown BS, Shah
AN, Menguy RB, Chey WY. Liver injury with alcoholic-like hyaline after gastroplasty for
morbid obesity. Gastroenterology. 1983;85:722-6.
20. Grim IS, Schindler W, Haluszka O.
Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J.
Gastroenterol. 1992; 87:775-9.
21. Powel EE,, Searle J, Mortuimer R.
Steatohepatitis associated with limb lipodistrophy. Gastroenterology . 1989; 97:1022-24.
22. Poucell S, Ireton J, Valencia-Mayoral
P, Downar E, Larratt L, Patterson J, et al. Amiodarone associated phospholipidosis and
fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies .
Gastroenterology. 1984; 86(5 pt 1): 926-36.
23. Pratt DS, KnoxTA, Erban J. Tamoxifen
induced steatohepatitis (letter). Ann Intern Med. 1995; 123-236.
24. Pessayre D, Bichara M. Degott C,
Potet F, Benhamou JP, Feldmann G. Perhexilene maleate induced cirrhosis. Gastroenterology
. 1979; 76:170-7.
25. Itoh S, Igarashi M, Tsukada Y,
Ichinoe A. Nonalcoholic fatty liver with alcoholic hyalin after long term glucocorticoid
therapy. Acta Hepatogastroenterol. Sttug). 1977; 24:415-8.
26. Seki K, Minami Y, Nishikawa M, Kawata
S, Miyoshi S, Imai Y, et al. "Nonalcoholic steatohepatitis" induced by massive
doses of sintetic. Gastroenterol Jpn. 1983;18:197-203.
27. Lombardi B. Considerations on the
pathogenesis of fatty liver. Lab Invest.1966;15(1 pt 1):1-20.
28. Navrelis PG, Ammon HV, Gleysteen JJ,
Komorowski RA, Charaf UK. Hepatic free fatty acids in alcoholic liver disease and morbid
obesity. J Clin Pathol. 1983; 3:221-31.
29. Wannless IR, Bargman JM, Oreopoulus
D, Vas SL. Subcapsular steatonecrosis in response to peritonealinsulin delivery: a clue to
the pathogenesis of steatonecrosis in obesity. Mod Pathol. 1989;2:69-74.
30. McGarry JD, Foster DW. Regulation of
hepatic acid fatty acid oxidation and ketone body production Annu Rev Biochem . 1980;
49:395-420.
31. Henry RR, Wallace P, OlefskyJM.
Effects of weight loss on mechanisms of hyperglicemya in obese non insulin dependent
diabetes. Diabetes 1986; 35:990-8.
32. Sherr HP, Nair PP, Whitte JJ, Bakwell
JG, Lockwood DH. Bile acid metabolism and hepatic disease following small bowell bypass
for obesity. Am J Clin Nutr. 1974; 27:1369-79.
33. Moxley RT 3d, PosefzkyT, Lockwood DH.
Protein nutrition and liver disease after jejunoileal bypass for morbid obesity. N Engl J
Med. 1974; 290:921-6.
34. Baddeley RM. An epilogue to
jejunoieal bypass. World J Surg. 1985; 9:842-9.
35. Marubbio AT Jr, Buchwald H, Schwartz
MZ, Varco R. Hepatic lessions of pericellular fibrosis in morbid obesity and after
jejunoileal bypass. Am J Clin Pathol. 1976; 66:684-91.
36. Fletcher LM, Kwoh-Gain I, Powel LW,
Halliday JW. Markers of chronic alcohol ingestion in patients with nonalcoholic
steatohepatitis: an aid to diagnosis. Hepatology. 1991; 13:455-9.
37. Van Ness MM, Diehl AM. Is liver
biopsy useful in the evaluation of patients with chronicallly elevated liver enzymes? Ann
Intern Med. 1989; 111:473-8.
38. Rogers DW, Lee CH, Pound DC, Kumar S,
Cummings OW, Lumeng L. Hepatitis C virus does not cause non-alcoholic steatohepatitis. Dig
Dis Scl. 1992; 37:1644-7.
39. Van Ness NM, Dick AM. Is liver biopsy
useful in the evaluation in the evaluation of patients with chronically elevated liver
enzymes? Ann Intern Med. 1989; III: 473-8.
40. Nasrallah SM, Wills Ce Jr, Galambos
TJ. Hepatic morphology in obesity. Dig Dis Sci. 1981; 26:325-7.
41. Linnen J, Wages J Jr, Zhang-keck ZY,
Fry KE, Krawczynsky KZ, Alter H, et al. Molecular cloning and disease association of
hepatitis G virus: a transfusion-transmisisble agent. Science. 1996; 271:505-8.
42. Nalpas B, Vassault AS, Le GuillouA,
Lesgourges B, Ferry N, Lacour B, et al. Serum activity of mitocondrial aspartate
aminotransferase: a sensitive marker of alcoholism with or without alcoholic hepatitis.
Hepatology. 1984; 4 893-6.
43. Hoffman AF. Bile acid hepatotoxicity
and the rationale of UDCA therapy in chronic cholestasis liver disease: some hypotheses.
In: Paumgertner G, Steihl; A, Barbaral, Roda E, eds. Strategies for the treatment of
hepatobiliary Diseases. Boston: Kluwer Academic 1990; 13-34.
44. Laurin J. Windor KD, Crippin JS, Gossard A, Gorers
GJ, Ludwing J, et al. Ursodeoxycollic acid or clofibrate in the treatment of non alcoholic
steatohepatitis. Induced steatohepatitis: a pilot study. Hepatology. 1996: 23:1464-7.
